Review anchor
D(2) dopamine receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
D(2) dopamine receptor
CHEMBL217
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats D(2) dopamine receptor as ChEMBL target CHEMBL217, mapped to UniProt P14416. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL217
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P14416
D(2) dopamine receptor
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why D(2) dopamine receptor matters
D(2) dopamine receptor is reviewed as D(2) dopamine receptor (UniProt P14416); D(2) dopamine receptor shows approved-linked disease relevance led by schizophrenia. 5 more disease programs remain visible in the same review block.; 32 linked drugs keep this evidence frame grounded.; the current evidence base includes 167 approved drugs, 14614 compounds, and 2456 assays, with lead potency reaching pChEMBL 11.0.
Protein context
D(2) dopamine receptor
D(2) dopamine receptor Sequence length is 443 aa.
Review this target as D(2) dopamine receptor, mapped to UniProt P14416. Sequence length is 443 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P14416
Protein
Disease context
schizophrenia
D(2) dopamine receptor shows approved-linked disease relevance led by schizophrenia. 5 more disease programs remain visible in the same review block. 32 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ARIPIPRAZOLE, ARIPIPRAZOLE LAUROXIL, ASENAPINE MALEATE.
Start review with schizophrenia because it currently carries approved-linked support. Linked drugs include ARIPIPRAZOLE, ARIPIPRAZOLE LAUROXIL, ASENAPINE MALEATE, BENPERIDOL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
32 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 167 approved drugs, 14614 compounds, and 2456 assays for this target. The dominant activity type is KI. CHEMBL157138 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL157138 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
167 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why D(2) dopamine receptor matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P14416, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why schizophrenia is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
14614
Total Compounds
2456
Total Assays
167
Approved Drugs
IC50: 2437.0, KI: 14732.0, EC50: 2208.0, KD: 130.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL157138
|
11.0 | EC50 | Clinical |
|
|
No preferred name
CHEMBL5201074
|
10.8 | Kd | — |
|
|
No preferred name
CHEMBL5200771
|
10.8 | Kd | — |
|
|
No preferred name
CHEMBL5198795
|
10.8 | Kd | — |
|
|
No preferred name
CHEMBL5183205
|
10.8 | Kd | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
GEPIRONE
CHEMBL284092
|
2023 |
|
|
LUMATEPERONE
CHEMBL3306803
|
2019 |
|
|
CARIPRAZINE HYDROCHLORIDE
CHEMBL2024517
|
2015 |
|
|
BREXPIPRAZOLE
CHEMBL2105760
|
2015 |
|
|
CARIPRAZINE
CHEMBL2028019
|
2015 |
|
|
VILAZODONE HYDROCHLORIDE
CHEMBL1615374
|
2011 |
|
|
VILAZODONE
CHEMBL439849
|
2011 |
|
|
LURASIDONE
CHEMBL1237021
|
2010 |
|
|
ILOPERIDONE
CHEMBL14376
|
2009 |
|
|
ASENAPINE
CHEMBL3187365
|
2009 |
|
|
BLONANSERIN
CHEMBL178803
|
2008 |
|
|
SILODOSIN
CHEMBL24778
|
2008 |
|
|
ARMODAFINIL
CHEMBL1201192
|
2007 |
|
|
ROTIGOTINE
CHEMBL1303
|
2006 |
|
|
PALIPERIDONE
CHEMBL1621
|
2006 |
|
|
ARIPIPRAZOLE
CHEMBL1112
|
2002 |
|
|
TEGASEROD MALEATE
CHEMBL1516474
|
2002 |
|
|
ZIPRASIDONE
CHEMBL708
|
2001 |
|
|
APOMORPHINE
CHEMBL53
|
2001 |
|
|
FROVATRIPTAN SUCCINATE
CHEMBL2138684
|
2001 |
|
|
PRAMIPEXOLE
CHEMBL301265
|
1997 |
|
|
FENOLDOPAM
CHEMBL588
|
1997 |
|
|
PRAMIPEXOLE DIHYDROCHLORIDE
CHEMBL3182733
|
1997 |
|
|
QUETIAPINE
CHEMBL716
|
1997 |
|
|
ROPINIROLE
CHEMBL589
|
1997 |
|
|
RALOXIFENE
CHEMBL81
|
1997 |
|
|
TAMSULOSIN
CHEMBL836
|
1997 |
|
|
OLANZAPINE
CHEMBL715
|
1996 |
|
|
SERTINDOLE
CHEMBL12713
|
1996 |
|
|
CABERGOLINE
CHEMBL1201087
|
1996 |
|
|
CARVEDILOL
CHEMBL723
|
1995 |
|
|
NEFAZODONE HYDROCHLORIDE
CHEMBL1200492
|
1994 |
|
|
CISAPRIDE
CHEMBL1729
|
1993 |
|
|
RISPERIDONE
CHEMBL85
|
1993 |
|
|
REMOXIPRIDE
CHEMBL22242
|
1990 |
|
|
EBASTINE
CHEMBL305660
|
1990 |
|
|
CLOZAPINE
CHEMBL42
|
1989 |
|
|
CLOMIPRAMINE
CHEMBL415
|
1989 |
|
|
PERGOLIDE
CHEMBL531
|
1988 |
|
|
HALOPERIDOL DECANOATE
CHEMBL1200986
|
1986 |
|
|
BUSPIRONE
CHEMBL49
|
1986 |
|
|
AMISULPRIDE
CHEMBL243712
|
1986 |
|
|
PIMOZIDE
CHEMBL1423
|
1984 |
|
|
MAPROTILINE
CHEMBL21731
|
1980 |
|
|
AMOXAPINE
CHEMBL1113
|
1980 |
|
|
METOCLOPRAMIDE
CHEMBL86
|
1979 |
|
|
BROMOCRIPTINE
CHEMBL493
|
1978 |
|
|
CLEMASTINE
CHEMBL1626
|
1977 |
|
|
LOXAPINE
CHEMBL831
|
1975 |
|
|
DOPAMINE HYDROCHLORIDE
CHEMBL1557
|
1974 |
Source Header